MULT3:BMFBOVESPAMultiplan Empreendimentos Imobiliarios SA Analysis
Data as of 2026-03-17 - not real-time
R$30.65
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Multiplan is trading around 30.65 BRL, which sits below its 20‑day SMA of roughly 33.1 but above the 200‑day SMA of 28.5, indicating a short‑term pullback within a longer‑term uptrend. The RSI at 38 suggests modest downside momentum, while the MACD shows a bearish signal with the histogram turning negative. Volume has been decreasing, adding pressure to the price, and the technical outlook points to a near‑term correction. On the valuation side, the DCF‑derived fair value of about 20.85 BRL places the current price well above intrinsic estimates, implying the stock is overvalued relative to fundamentals. Nevertheless, the dividend yield of 4% and a payout ratio near 44% make the dividend component attractive, and the company’s strong operating margins (>70%) and solid free cash flow support dividend sustainability.
Fundamentally, revenue has slipped by roughly 3.7% year‑over‑year, yet profit margins remain robust at over 40%, and ROE is near 19%. The balance sheet is heavily leveraged, with a debt‑to‑equity ratio close to 87%, though cash flow generation appears sufficient to service debt. Compared with an industry average P/E of 32.8, MULT3’s P/E of 13 is low, but the high debt and overvaluation by DCF temper optimism. The stock’s low beta (≈0.34) suggests limited price volatility relative to the market, while the 30‑day volatility of nearly 30% signals notable price swings. Overall, the blend of attractive dividend yield, solid margins, and overvaluation creates a nuanced picture for investors.
Fundamentally, revenue has slipped by roughly 3.7% year‑over‑year, yet profit margins remain robust at over 40%, and ROE is near 19%. The balance sheet is heavily leveraged, with a debt‑to‑equity ratio close to 87%, though cash flow generation appears sufficient to service debt. Compared with an industry average P/E of 32.8, MULT3’s P/E of 13 is low, but the high debt and overvaluation by DCF temper optimism. The stock’s low beta (≈0.34) suggests limited price volatility relative to the market, while the 30‑day volatility of nearly 30% signals notable price swings. Overall, the blend of attractive dividend yield, solid margins, and overvaluation creates a nuanced picture for investors.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- price below 20‑day SMA
- bearish MACD signal
- decreasing volume trend
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- attractive 4% dividend yield
- strong operating margins and cash flow
- valuation gap between market price and DCF fair value
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- low beta indicating stability
- high dividend sustainability
- elevated debt level requiring monitoring
Key Metrics & Analysis
Financial Health
Revenue Growth-3.70%
Profit Margin41.66%
P/E Ratio13.3
ROE19.11%
ROA9.09%
Debt/Equity86.86
P/B Ratio2.4
Op. Cash FlowR$1.5B
Free Cash FlowR$1.1B
Industry P/E32.8
Technical Analysis
TrendBullish
RSI38.6
SupportR$0.00
ResistanceR$35.96
MA 20R$33.11
MA 50R$31.70
MA 200R$28.51
MACDBearish
VolumeDecreasing
Fear & Greed Index79.39
Valuation
Fair ValueR$20.85
Target PriceR$36.29
Upside/Downside18.41%
GradeOvervalued
TypeValue
Dividend Yield4.00%
Risk Assessment
Beta0.34
Volatility29.50%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.